Pulmonary Arterial Hypertension (PAH) – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030


 Pulmonary arterial hypertension (PAH) is a chronic and progressive disorder characterized by antiproliferative vasculopathy in the pulmonary arterioles, leading to endothelial and smooth muscle proliferation and dysfunction, inflammation, and thrombosis.

·       As per Thelansis’ research, the total prevalent cases of Pulmonary Arterial Hypertension (PAH) in 8 major markets ranges from 129,857 in 2018 to 148,655 by 2030. Idiopathic PAH is the most commonly found form of Pulmonary Arterial Hypertension (PAH). Higher Prevalence of Pulmonary Arterial Hypertension is observed among females as compared to males in 8MM countries

·       Among the diseases associated with PAH, it was observed by the Thelansis research team that around ~50% of patients are associated with Connective Tissue Disease (CTD), and ~19% have Congenital Heart Disease (CHD), and ~11% suffer from portal hypertension

·       The current therapeutic landscape for approved therapies is dominated by Janssen (acquired from Actelion). Their PAH portfolio includes ERAs (macitentan, bosentan) PCs (selexipag, Iloprost, epoprostenol). PAH market is now moving more and more towards upfront dual and triple combinations, which combine several mechanisms like ambrisentan + tadalafil from GSK, which combines ERA and PDE5i mechanisms

 

The competitive landscape of Pulmonary Arterial Hypertension (PAH) includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Pulmonary Arterial Hypertension (PAH) across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Pulmonary Arterial Hypertension (PAH) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Pulmonary Arterial Hypertension (PAH) – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          Apabetalone      Resverlogix Corp           Phase 1

2          ACT-293987     Actelion Phase 3

3          LIQ861 Inhaled Treprostinil        Liquidia Technologies, Inc.            Phase 3

4          Tadalafil- Tablet or Oral suspension       Eli Lilly and Company            Phase 2

5          TPN171H          Vigonvita Life Sciences  Phase 2

6          JTT-251            Akros Pharma Inc.         Phase 2

7          Sotatercept       Acceleron Pharma, Inc. Phase 3

8          GMA301           Gmax Biopharm LLC.    Phase 1

9          GB002  Gossamer Bio Inc.         Phase 2

10        Ranolazine        Gilead Sciences            Phase 3

Continued..

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
 Herpes simplex virus (HSV) causes an infection that affects the external genitalia, anal region, mucosal surfaces, and skin in other body parts. Herpes simplex virus is a ubiquitous, host-adapted pathogen that causes various disease states. There are two types of HSV with two distinct DNA viruses, type 1 (HSV-1) and type 2 (HSV-2). Both the types are closely related but differ epidemiologically. HSV-1 is traditionally associated with orofacial disease by affecting the mouth and lips with fever blisters and cold sores, whereas HSV-2 is associated traditionally with genital disease infecting genitals and rectum area with sores and is classified as STD (sexually transmitted disease). As HSV-1 is associated with genital infections more often than HSV-2, lesion location is not necessarily of viral type. HSV can spread through direct contact. Almost 80% of Herpes simplex infections are asymptomatic, while symptomatic infections can be characterized by significant morbidity and recurrenc...
Read more

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
Thelansis’s “HR+/HER2- Breast Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential HR+/HER2- Breast Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of HR+/HER2- Breast Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs. HR+/HER2- Breast Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model,...
Read more